MARKET SURVEY OF ANTITUBERCULOSIS DRUGS IN INDIA

Authors

  • Ashish Pandey Sunder Deep Pharmacy College, Ghaziabad, UP, India

Keywords:

Gatifloxacin, Ethionamide, Aminosalicylic Acid

Abstract

Tuberculosis (TB) is a contagious disease. It is worldwide occurring disease affecting millions of people. A WHO report in 2011 show that almost 8.7 million people is in apprehension of Tuberculosis. Tuberculosis commonly affects to lungs but other body part is also susceptible to develop tuberculosis viz. brain, bone, spine, kidney, lymph node. Mycobacterium tuberculosis a gram positive bacteria is responsible for this contagious disease. Streptomycin is the first drug invented to treat tuberculosis. Some other also useful anti-tuberculosis drugs are invented like isoniazid, ethambutol, rifampin, pyrazinamide. Due to noncompliance and other reasons drug resistance should be developed in patients then other drugs come in addition like  gatifloxacin, ethionamide, aminosalicylic acid, cycloserine, amikacin etc but these drugs have high toxic effects than first line drugs. WHO begun a programme to fight against tuberculosis named DOTS (Directly Observed Treated,Shortcourse). This study approved that the selling of first line drugs viz. ethambutol, isoniazid, rifampin, pyrazinamide and their combination is more than the second line drugs in India.

 

KEY WORDS: Gatifloxacin, Ethionamide, Aminosalicylic Acid, Cycloserine, Amikacin.

Downloads

Published

2013-06-30

Issue

Section

Articles